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The pathogenetic mechanisms underlying tendinopathy remain unclear, with much debate as to whether inflammation or
degradation has the prominent role. Increasing evidence points toward an early inflammatory infiltrate and associated inflammatory
cytokine production in human and animal models of tendon disease.The IL-21/IL-21R axis is a proinflammatory cytokine complex
that has been associated with chronic inflammatory diseases including rheumatoid arthritis and inflammatory bowel disease. This
project aimed to investigate the role and expression of the cytokine/receptor pair IL-21/IL-21R in human tendinopathy. We found
significantly elevated expression of IL-21 receptormessage and protein in human tendon samples but found no convincing evidence
of the presence of IL-21 at message or protein level. The level of expression of IL-21R message/protein in human tenocytes was
significantly upregulated by proinflammatory cytokines (TNF𝛼/IL-1𝛽) in vitro. These findings demonstrate that IL-21R is present
in early human tendinopathy mainly expressed by tenocytes and macrophages. Despite a lack of IL-21 expression, these data again
suggest that early tendinopathy has an inflammatory/cytokine phenotype, which may provide novel translational targets in the
treatment of tendinopathy.
1. Introduction
Overuse tendon injuries, namely, tendinopathies, pose a
significant clinical problem in musculoskeletal medicine
[1]. The intrinsic pathogenetic mechanisms underlying the
development of tendinopathies are largely unknown [2, 3];
however, several model systems have recently implicated
proinflammatory cytokines [4–6]. The interaction between
cytokine production and inflammation is critical to tissue
homeostasis and plays a key role in many diseases including
rheumatoid arthritis and cardiovascular disease. Previous
studies highlight a huge influx of inflammatory cells, partic-
ularly mast cells [7, 8], at the site of tendon injury with the
subsequent release of growth factors and cytokines [9, 10].
These factors chemotactically promote innate immune cell
migration into the injured tissue and produce cytokines and
growth factors (e.g., TGF-𝛽, IGF-1, and basic FGF) in an
attempt to produce tissue resolution [11, 12].
Tenocytes demonstrate endogenous expression of various
cytokines such as TNF-𝛼, IL-1𝛽, IL-6, IL-10, VEGF, and TGF-
𝛽 [13–15]. Increased amounts of IL-1𝛼, IL-1𝛽, TNF-𝛼, and
IFN-𝛾 were present in inflamed native equine tendon [16],
while inflammatory gene expression was altered in a rodent
supraspinatus tendon overuse model [17]. Mechanical factors
also influence tendon cytokine profile whereby cyclic strain
has been shown to induce VEGF expression in tenocytes [18].
Conversely, stress deprivation leads to an overexpression of
cytokines including IL-1𝛽 and TNF-𝛼 in the patellar tendon
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with subsequent mechanical deterioration of the tendon [19]
with additional investigation in IL-6 deficient mice show-
ing decreased tendon healing properties [5]. These results
fit the pathogenetic theory that inflammation drives early
tendinopathy, when microrupture of tendon induces expres-
sion of damage-associatedmolecular patterns (DAMPs) in an
attempt to produce tissue healing [20].
IL-21 is a proinflammatory cytokine of the IL-1 family and
is produced mainly by CD4+ lymphocytes and natural killer
T cells (NK) [21]. It is known tomodulate T-cell proliferation,
B-cell differentiation, and cytotoxic properties of NK cells, as
well as the antigen presenting and T-cell activating abilities
of dendritic cells [22]. The IL-21 receptor is composed of a
specific IL-21 receptor alpha chain and the common gamma
chain receptor and has been found to be expressed at
significantly higher mRNA levels and by immunohistochem-
ical staining in biopsy samples from patients with systemic
sclerosis and rheumatoid arthritis (RA), compared to controls
[23, 24]. Furthermore, IL-21R is present in higher levels
in synovial fibroblasts and macrophages in RA, activating
fibroblasts independently of TNF-𝛼 and IL-1𝛽 [25].
The purpose of this study was to investigate the presence
and role of IL- 21 and IL-21R in human tendinopathy and was
borne out of preliminary studies in animal and human mod-
els of tendinopathy in which the proinflammatory cytokines
were found in increased levels [9, 26].
2. Materials and Methods
2.1. Human Model of Tendinopathy. All procedures and pro-
tocols were approved by the South East Area Sydney Ethics
Committee under ACEC no. 99/101 and NHS Greater Glas-
gow Research Ethics Committee (West Section). All patients
gave informed consent as per the study protocol. Fifteen
supraspinatus tendon samples were collected from patients
with rotator cuff tears undergoing shoulder surgery (Table 1).
The mean age of the rotator cuff ruptured patients was 54
years (range, 35–70 years) and themean tear size was 2.5 cm2.
Samples of the subscapularis tendon were also collected from
the same patients. Patients were only included if there was no
clinically detectable evidence of subscapularis tendinopathy
on a preoperative MRI scan or macroscopic damage to
the subscapularis tendon at the time of arthroscopy—by
these criteria they represented a truly preclinical cohort.
An independent control group was obtained comprising
10 samples of subscapularis tendon collected from patients
undergoing arthroscopic surgery for shoulder stabilization
without rotator cuff tears. The absence of rotator cuff tears
was confirmed by arthroscopic examination. The mean age
of the control group was 35 years (range, 20–41 years).
2.2. Tissue Collection and Preparation. Arthroscopic repair
of the rotator cuff was carried out using the standard three-
portal technique as described previously [27]. The cross-
sectional size of the rotator cuff tear was estimated and
recorded as described previously [28]. The subscapularis
tendon was harvested arthroscopically from the superior
border of the tendon 1 cm lateral to the glenoid labrum.
The supraspinatus tendon was harvested from within 1.5 cm
of the edge of the tear prior to surgical repair. For immuno-
histochemical staining the tissue samples were immediately
fixed in 10% (v/v) formalin for 4 to 6 hours and then
embedded in paraffin. Sections were cut to 5𝜇m thickness
using a Leica-LM microtome (Leica Microsystems, Ger-
many) and placed onto Superfrost Ultra Plus glass slides
(GerhardMenzel, Germany).The paraffin was removed from
the tissue sections with xylene, rehydrated in graded alcohol,
and used for histological and immunohistochemical staining
per previously established methodologies [29].
2.3. Immunohistochemistry. For immunohistochemical stud-
ies, samples were rehydrated through a graded alcohol/xylene
series and endogenous peroxide activity was blocked using
0.5% H
2
O
2
in methanol. Antigen retrieval was performed in
0.01M citrate buffer at pH 6.0 for 30 minutes. Nonspecific
binding was blocked using 2.5% horse serum and 2.5%
human serum in TBST. Avidin/biotin block was carried out
using avidin D for 15 minutes, followed by biotin for 15 min-
utes. Primary antibody, rabbit anti-human polyclonal IL-21
antibody (Lifespan Biosciences, Seattle, WA, USA), was then
followed by biotinylated goat anti-rabbit IgG as the secondary
antibody. Slides were then incubated with Vectastain ABC
kit and staining was visualized using Chromogen ImmPACT
DAB, counterstainedwith haematoxylin. For IL-21R staining,
mouse anti-human IL-21R primary antibody was used fol-
lowed by biotinylated horse anti-mouse secondary antibody
and conjugated with tyramide (Perkin Elmer, Waltham,
MA, USA) via HRP. Positive (human tonsil tissue, human
rheumatoid arthritis tissue) and negative control specimens
were included, in addition to the surgical specimens for each
individual antibody staining technique. Omission of primary
antibody and use of negative control isotypes confirmed the
specificity of staining.
We applied a scoring system based on previous methods
to quantify the immunohistochemical staining [8]. Five
random high power fields (×400) were evaluated by three
independent assessors (NLM, JHR, ALC). In each field the
number of positive and negatively stained cells was counted
and the percentage of positive cells was calculated giving the
following semiquantitative grading, grade 0 = no staining,
grade 1 ≤ 10% cells stained positive, 2 = 10–20% cells stained
positive, and grade 3 ≥ 20% cells positive.
2.4. Tenocyte Culture. Human tendon derived cells were
explanted from hamstring tendon tissue of 5 patients (age 18–
30 years) undergoing hamstring tendon ACL reconstruction.
Cultures weremaintained at 37∘C in a humidified atmosphere
of 5%CO
2
for 28 days. Cells were subcultured and trypsinized
at subconfluency, Cells from the 3rd passage were used in
normoxic conditions.
2.5. RNA Extraction and PCR. RNA was isolated from cells
with Trizol followed by QIAgen RNEasy Kit (Qiagen, Craw-
ley, UK) with additional DNase step. cDNA was prepared
from mRNA with AffinityScript (Agilent Technologies, CA,
USA) per manufacturer instructions. SYBR green real-time
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Figure 1: IL-21R message and protein in human tendinopathy. (a) The levels of mRNA (2−ΔΔCT) for IL-21R were determined by real-time
PCR in torn tendon and early tendinopathy samples. Data are shown as the mean fold change ± SD of triplicate samples compared to control
samples corrected to GAPDH and are representative of experiments using 12 individual donors of tendon tissue (∗𝑃 < 0.05, ∗∗𝑃 < 0.01).
(b) Semiquantitative scoring of IL-21R protein expression in tendon samples. Graphs illustrate relative expression of corresponding proteins
in human tendon samples. Histological scoring system, 0 = no staining, 1 ≤ 10% cells positive, 2 = 10–20% cells positive, grade 3 ≥ 20%
cells positive. Data displayed as mean ± SEM, 𝑛 = 12 for supraspinatus and matched subscapularis, 𝑛 = 10 for control group. (∗𝑃 < 0.05,
∗∗
𝑃 < 0.01).
Table 1: Patient demographics and rotator cuff tear size.
Tear size Control Small (<1 cm2) Medium (>1–3 cm2) Large (>3–5 cm2) Massive (>5 cm2)
Number of cases 10 6 6 3 3
Male : female ratio 8 : 2 4 : 2 3 : 3 2 : 1 1 : 2
Mean age in years (range) 35 (20–41) 55 (39–60) 58 (48–64) 54 (47–60) 66 (50–78)
Mean duration of symptoms in months (range) 6.2 (1–14) 8.1 (2–18) 6.8 (3–12) 9.8 (4–22) 6.9 (2–15)
Mean number of steroid injections 0 1.6 1.2 1.3 1.8
PCR was performed (Applied Biosystems, CA, USA) with
ABI Prism 7900HT sequence detection system (AB) and all
samples were normalized toGAPDH, the housekeeping gene.
2.6. Statistical Analysis. Significance was assessed with two-
way paired Student’s t-tests (RT-PCR), Mann-Whitney U
tests (histological staining comparison), and Kruskal-Wallis
one-wayANOVA (patient comparison data) usingGraph Pad
PRISM 5 software (La Jolla, CA, USA). Statistics reported on
real-time PCR data represent the mean of each experiment
repeated in triplicate and then the pooled mean of 𝑛 = 3 or 5.
3. Results
3.1. Expression Levels of IL-21R in Human Tendinopathy.
IL-21R message and protein was significantly upregulated
compared to control and torn tendon samples (Figure 1). In
contrast to IL-21R, expression of IL-21 mRNA could not be
detected in any tissue samples from the same tendon biopsy
patients. There were no significant correlations between IL-
21R expression and the mean duration of symptoms, patient
age, or number of steroid injections.
Torn tendon samples exhibited marked degeneration,
mucoid change, and frank chondroid metaplasia (grade 4),
whereas matched subscapularis tendon biopsies had grade-
2-3 changes indicative of early tendinopathy as previously
reported [26]. All control samples were classified as grade
1 consistent with normal fibrotendinous tissue with large
distinct collagen fibrils.Therewere no significant correlations
between Bonar score and the mean duration of symptoms
or patient age. IL-21R was mainly expressed by cells in the
sublining layer and by cells within the extracellular matrix
in the early tendinopathy group (Figure 2). Within the torn
group, only mild staining was noted in the sublining layer
with minimal staining within the matrix. The majority of
positive cells were tenocytes (confirmed with CD55 back to
back staining) while further back to back staining with CD68
(macrophage) marker revealed a few (<10%) cells to be of
macrophage lineage.
3.2. Expression of IL-21R by Tenocytes In Vitro. IL-21R has
been reported to be expressed in fibroblasts derived from
synovial tissue [30].Therefore, tendon fibroblasts were exam-
ined for their expression of IL-21 by IHC. Although no
specific cell surface markers exist for tenocytes, we chose the
surface marker CD55 that has been used by a collaborating
laboratory (P.P.Tak) as a fibroblast marker to check assurance
the cultured cells were indeed fibroblasts. IL-21Rwas detected
in in vitro cultured tenocytes at both the message and protein
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Figure 2: Immunohistochemical staining for IL-21R in human tendinopathy. IL-21R staining from control tendon, torn tendon, and early
tendinopathy at ×10 and ×40 magnification stained for Isotype IgG in bottom left corner.
level (Figure 3). Once again no expression of IL-21 message
or protein was found in cultured tenocytes.
3.3. Upregulation of IL-21R by Proinflammatory Cytokines
In Vitro. Next we examined whether IL-21R expression on
tenocytes is regulated by proinflammatory cytokines. To this
end, tenocytes were stimulated with IL-1𝛽 or TNF-𝛼, two
cytokines which are produced in excess in tendinopathy
and known to regulate fibroblast activity. Both cytokines
upregulated IL-21R expression and message (𝑃 < 0.01) and
protein levels (Figure 3) with themost significant change seen
in combination.
4. Discussion
Our study provides evidence that IL-21R is present in early
tendinopathy and can be modulated in tenocytes by proin-
flammatory cytokines promoting the concept of IL-21R as
inflammatory regulator in early tendon tissue damage.
Recent genome-wide association studies have provided
convincing evidence that the chromosomal 4q27 region
harboring the IL-2 and IL-21 genes is associated with
chronic inflammatory disorders, including coeliac disease
(a gluten-sensitive enteropathy), psoriasis, diabetes, rheuma-
toid arthritis, inflammatory bowel disease (IBD), asthma, and
systemic lupus erythematosus (SLE) [31–33]. However, the
precise role of the IL-21/IL-21R axis in fibroblasts and thus
stromal cell pathologies remains to be established. IL-21R
expression was found to be markedly increased in systemic
sclerosis patients with skin biopsies showing keratinocytes
as the predominant source of IL-21R [34]. IL-21R is also
highly expressed in synovial macrophages and fibroblasts
of rheumatoid arthritis (RA) patients [24]. T cells derived
from the peripheral blood or synovial fluid of these patients
produced high levels of Th1 cytokines after stimulation
with IL-21, whereas blockade of IL-21 with the IL-21R/Fc
fusion protein significantly inhibits inflammatory cytokine
production in RA synovial membrane cultures [35]. Herein
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Figure 3: Upregulation of IL-21R in tenocytes in vitro. (a) The levels of mRNA (2−ΔΔCT) for IL-21R were determined by real-time PCR in
explanted tenocytes in vitro following stimulation with IL-1, TNF, and in combination. Data are shown as the mean fold change ± SD of
triplicate samples compared to no stimulated cells corrected to GAPDH and are representative of experiments using five individual donors
of tendon explant tissue. (b) Immunostaining for IL-21R in explant tenocyte cultures stimulated as in (a) confirming changes at protein level.
we, demonstrate significantly increased IL-21R expression
in early tendinopathy similar to that reported in RA and
SSc suggesting an “activated” IL-21R+ tenocyte phenotype
to be involved in the inflammatory milieu of early tendon
disease.Thismay contribute to tendonweakening in a similar
manner to activated fibroblasts contributing to joint erosion
in RA where it is has been shown that the IL-21/IL-21R
axis is involved in dysregulated matrix metalloproteinase
production [36].
More recently it has been demonstrated that IL-21 might
also function as an important mediator of the crosstalk
between immune and nonimmune cells, given that it can
enhance the production of chemokines and tissue-degrading
matrix metalloproteinases (MMPs) by epithelial cells [37]
and fibroblasts [38]. Interestingly IL-21 was not detected by
immunohistochemistry or real-time PCR which may suggest
alternative ligands binding to IL-21R in tendinopathy. This
theory has been proposed for RA as some receptors bind
multiple cytokines; for instance, type II receptor complexes
consisting of IL-4R𝛼 and IL-13R𝛼1 heterodimers are activated
by both IL-4 and IL-13 [39]. We have previously reported
increased levels of IL-15 in early tendinopathy, which shares
common cytokine receptor 𝛾-chain (𝛾
𝑐
), which is a functional
component of the IL-21R complex [40]. Thus it may be
that downstream activation of the IL-21R complex occurs in
tendinopathy via IL-15 costimulation or alterative cytokine
interactions. Secondly it may be that IL-21 expression occurs
extremely early in the “tendinopathy spectrum” and that our
cohort represents a later stage in the pathological process;
however, we feel that the alternative ligand binding theory
6 Mediators of Inflammation
of IL-21R is a more likely scenario within tendinopathy
pathology.
There are limitations inherent in our study. Firstly, as
the control group was substantially younger than the patient
group, age-related changes within the tendon samples could
contribute to the degenerative picture and inflammatory
cell expression seen in the matched subscapularis tendons.
However, the lack of degenerative change on MRI and
arthroscopic examinations suggests that the differences are
truly at the cellular level as suggested by our work. Secondly,
subscapularis tendon is functionally and organizationally
distinct from supraspinatus and thus responds to mechanical
loading in a different manner which may alter its cellular
profile. Also control samples from subscapularis undergoing
stabilization may not be truly “normal” controls but are
currently the best available control tendon sample and this is
reflected by a Bonar score of 0. It is reassuring, however, that
we found the same inflammatory and vascular cell subtypes
in matched subscapularis tissue indicating that the inflam-
matory response may be uniform within joints subjected
to tendon degeneration. In addition having subscapularis
samples from the same patient eliminates bias that may result
from variation between individuals and has been previously
shown to be useful method in sampling of tissues.
5. Conclusion
On the basis of these results we propose IL-21R as a potential
inflammatory mediator in tendinopathy. Better understand-
ing of the pathological cascade involving IL-21R could lead to
the development of cell targeted treatmentmodalities in early
human tendon disease.
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